| Nov 15 |
Nuvectis Pharma reports data from Phase 1b study of NXP800
|
| Nov 14 |
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
|
| Nov 14 |
Nuvectis sinks after early-stage data for ovarian cancer therapy
|
| Nov 14 |
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
|
| Nov 13 |
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
|
| Nov 5 |
Nuvectis Pharma GAAP EPS of -$0.24 beats by $0.01
|
| Nov 5 |
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
|
| Oct 28 |
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
|
| Oct 7 |
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
| Sep 16 |
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
|
